SPAC1851.02 Antibody

Basic Research Questions

• What is SPAC1851.02 and why is it studied in fission yeast research?

  SPAC1851.02 (slc1) is an uncharacterized acyltransferase in Schizosaccharomyces pombe (fission yeast), specifically predicted to function as a 1-acylglycerol-3-phosphate O-acyltransferase . Studying this protein contributes to our understanding of lipid metabolism in eukaryotic cells. S. pombe serves as an excellent model organism with well-characterized autonomous replication sequence (ARS) elements that function as origins of replication in vivo . The protein has been investigated in the context of chromatin-associated functions, although its precise role is still being elucidated through ongoing research.

• What types of SPAC1851.02 antibodies are currently available for research?

  Currently, the following antibody types targeting SPAC1851.02 are available for research:

  Antibody Type	Host	Applications	Purity	Target Species
  Polyclonal Antibody	Rabbit	ELISA, Western Blot	Antigen-affinity purified	S. pombe (strain 972/24843)
  Monoclonal Antibodies*	Various	Varies by supplier	≥85% as determined by SDS-PAGE	S. pombe

  *Note: Similar to other S. pombe proteins like Swi6, both monoclonal and polyclonal options exist, with polyclonal being more common for less-characterized proteins .

• What are the recommended applications for SPAC1851.02 antibodies?

  SPAC1851.02 antibodies have been validated for several experimental applications:

  • Western Blotting (WB): For detecting the protein in cell lysates with expected molecular weight

  • Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection

  • Immunoprecipitation (IP): For protein complex isolation studies

  • Chromatin Immunoprecipitation (ChIP): If the protein associates with chromatin

  These applications have been validated through rigorous testing following standard antibody validation methods that include positive and negative controls . The antibody's specificity should be verified before use in critical experiments, especially when studying novel interactions.

Intermediate Research Methodology Questions

• What protocol modifications are recommended for SPAC1851.02 antibody in pull-down experiments with S. pombe?

  For effective pull-down experiments using SPAC1851.02 antibodies in S. pombe, follow these methodological adaptations:

  1. Cell lysis optimization: Use spheroplast preparation with lysing enzyme (0.3 mg/ml) and zymolase 20T (0.3 mg/ml) until OD600 is reduced to <10% of starting value .

  2. Buffer composition: Use buffer N (20 mM Hepes·NaOH, pH 7.6, 50 mM NaCl, 10 mM magnesium acetate, 1 mM ATP, 0.02% NP-40, and protease inhibitors) with 1% Triton X-100 for extraction .

  3. Antibody binding: For polyclonal SPAC1851.02 antibodies, incubate with cell extract for at least 1 hour at 4°C before adding protein A beads. For antibodies with low affinity to protein A (like mouse IgG1), use a secondary antibody during immunoprecipitation to improve binding efficiency .

  4. Washing conditions: Perform at least five washes with 1 ml of buffer containing 0.2% NP-40 and 0.1 M NaCl. Additional washes may reduce background but could also reduce yield .

  5. Elution strategy: Boil beads in SDS sample buffer (62.5 mM Tris·HCl, pH 6.8, 1% SDS, 2.5% 2-mercaptoethanol, 5% glycerol) for 5 minutes before SDS-PAGE analysis .

  These modifications account for the specific properties of S. pombe cells and ensure optimal extraction and immunoprecipitation of SPAC1851.02 protein complexes.

• How can I validate the specificity of a newly acquired SPAC1851.02 antibody?

  A comprehensive validation approach for SPAC1851.02 antibodies should include:

  1. Knockout/knockdown validation: Compare antibody signal in wild-type versus SPAC1851.02 knockout or knockdown S. pombe strains. A specific antibody should show significantly reduced or absent signal in knockout/knockdown samples .

  2. Multiple antibody confirmation: Test multiple antibodies targeting different epitopes of SPAC1851.02. Similar staining patterns increase confidence in specificity .

  3. Biological validation: Verify that detected localization or protein interactions align with known biology of SPAC1851.02 or acyltransferases in general. This may include examining co-localization with other enzymes involved in lipid metabolism .

  4. Recombinant protein validation: Perform Western blot analysis using recombinant SPAC1851.02 protein (available from expression in E. coli, yeast, or other systems). A band at the expected molecular weight confirms specificity .

  5. Cross-reactivity assessment: Test antibody against closely related proteins to ensure it doesn't recognize unintended targets, especially other acyltransferases in S. pombe .

  Document all validation experiments thoroughly, including positive and negative controls, to ensure reproducibility and reliability of subsequent research findings.

• What are the recommended controls when using SPAC1851.02 antibody in chromatin immunoprecipitation experiments?

  When conducting ChIP experiments with SPAC1851.02 antibodies, implement these essential controls:

  1. Input DNA control: Reserve a portion (5-10%) of chromatin before immunoprecipitation to normalize for DNA abundance differences between samples.

  2. Isotype control antibody: Use a non-specific antibody of the same isotype and host species to establish background signal levels.

  3. Positive genomic locus control: Include primers for regions where SPAC1851.02 is expected to bind (based on preliminary data or related acyltransferase studies).

  4. Negative genomic locus control: Include primers for regions unlikely to be bound by SPAC1851.02 (heterochromatic regions or genes with unrelated functions).

  5. Known antibody control: If studying chromatin association, include a well-characterized chromatin-associated protein antibody (such as anti-Swi6) as a technical positive control .

  6. Protein tag orthogonal validation: If possible, compare results from the SPAC1851.02 antibody with results from an epitope-tagged version of the protein (HA or FLAG tag) to verify consistency in binding patterns .

  These controls ensure the specificity and validity of ChIP results when studying a less-characterized protein like SPAC1851.02.

Advanced Research Questions

• How can I resolve contradictory results between SPAC1851.02 antibody detection and genetic expression data?

  Contradictions between antibody detection and expression data may stem from several factors:

  1. Post-translational regulation: SPAC1851.02 may undergo modifications affecting epitope accessibility without changing mRNA levels. Investigate potential phosphorylation, acetylation, or other modifications using phospho-specific antibodies or mass spectrometry.

  2. Protein stability dynamics: Determine protein half-life through cycloheximide chase experiments compared to mRNA stability to identify discrepancies in turnover rates.

  3. Antibody epitope masking: The antibody epitope might be masked in certain protein complexes or conformational states. Try multiple antibodies targeting different epitopes or use native versus denaturing conditions to compare results.

  4. Subcellular localization changes: SPAC1851.02 might relocalize without changing total abundance. Compare immunofluorescence or cell fractionation data with total protein measurements.

  5. Technical validation approach: Follow a structured antibody validation workflow including:

     • Western blotting with recombinant SPAC1851.02 protein

     • Immunoprecipitation followed by mass spectrometry

     • Testing in slc1 deletion strains

     • Cross-referencing with tagged versions of the protein

  When publishing contradictory results, thoroughly document all validation methods and explicitly discuss potential reasons for discrepancies to advance understanding of this poorly characterized protein.

• What methodological approaches can differentiate between SPAC1851.02 and other acyltransferases in S. pombe when studying protein-protein interactions?

  To ensure specificity when studying SPAC1851.02 interactions:

  1. Sequential immunoprecipitation: Perform tandem immunoprecipitation using both SPAC1851.02 antibody and antibodies against suspected interaction partners. True interactions should be reproducible in both directions.

  2. Recombinant protein interaction validation: Express recombinant SPAC1851.02 and test direct interactions with purified partners in vitro using techniques like surface plasmon resonance or isothermal titration calorimetry.

  3. Proximity-based labeling: Employ BioID or APEX2 proximity labeling by fusing these enzymes to SPAC1851.02 to identify proteins in close proximity in vivo, followed by streptavidin pull-down and mass spectrometry.

  4. Domain-specific mutations: Create point mutations in functional domains of SPAC1851.02 and assess their impact on specific interactions to identify domains responsible for each interaction.

  5. Cross-linking mass spectrometry: Use chemical crosslinkers followed by immunoprecipitation and mass spectrometry to capture transient interactions and identify direct binding partners.

  6. Comparative interactome analysis: Compare the interactomes of multiple acyltransferases in S. pombe to identify unique versus common interaction partners of SPAC1851.02.

  This multi-method approach provides higher confidence in specificity than single-method investigations, particularly important for enzymes with similar catalytic functions.

• How can I optimize SPAC1851.02 antibody conditions for detecting low-abundance chromatin-associated complexes?

  For detecting low-abundance SPAC1851.02 chromatin complexes:

  1. Chromatin extraction optimization: Use DNase I treatment (1,000 units/ml) at 4°C for 30 minutes followed by higher salt extraction (0.5-1.0M NaCl rather than 0.3M) to ensure complete solubilization of chromatin-bound proteins .

  2. Cross-linking strategies:

     • For protein-protein interactions: Use DSP (dithiobis(succinimidyl propionate)) at 1-2 mM

     • For protein-DNA interactions: Use formaldehyde at 1% for 10 minutes

     • For challenging complexes: Consider dual crosslinking with both DSP and formaldehyde

  3. Signal amplification techniques:

     • Employ tyramide signal amplification for immunofluorescence

     • Use high-sensitivity detection systems for Western blots (e.g., femto-level chemiluminescent substrates)

     • Consider mass spectrometry with targeted approaches (PRM or MRM) for verification of specific interactions

  4. Specialized immunoprecipitation conditions:

     • Pre-clear lysates with protein A/G beads to reduce background

     • Include competitors for non-specific interactions (e.g., salmon sperm DNA for DNA-binding proteins)

     • Use specialized low-binding tubes to prevent sample loss

     • Optimize antibody-to-lysate ratios through titration experiments

  5. Consider epitope-tagged approaches: Compare results with epitope-tagged versions of SPAC1851.02 using high-affinity tag antibodies (HA or FLAG), which can sometimes provide higher sensitivity than antibodies against the native protein .

  Document all optimization steps and include appropriate controls to ensure reproducibility of the refined protocol.

• What are the latest methodological advances for studying SPAC1851.02 dynamics during cell cycle progression in S. pombe?

  Recent methodological advances for studying SPAC1851.02 dynamics include:

  1. Live-cell imaging techniques:

     • FRAP (Fluorescence Recovery After Photobleaching) with fluorescently tagged SPAC1851.02

     • SPT (Single Particle Tracking) for monitoring protein movement within cellular compartments

     • RICS (Raster Image Correlation Spectroscopy) for measuring diffusion rates and binding kinetics

  2. Cell cycle synchronization approaches:

     • Lactose gradient centrifugation for minimally perturbing synchronization

     • Cdc25-22 temperature-sensitive mutants for G2 arrest and release

     • Hydroxyurea block and release for S-phase analysis

  3. Degradation tagging systems:

     • Auxin-inducible degron (AID) system adapted for S. pombe

     • SMASh tag for reversible protein depletion

     • dTAG system for rapid targeted protein degradation

  4. Quantitative proteomics strategies:

     • TMT (Tandem Mass Tag) labeling for comparing SPAC1851.02 abundance across cell cycle stages

     • SILAC (Stable Isotope Labeling by Amino acids in Cell culture) for quantitative interaction studies

     • Parallel Reaction Monitoring (PRM) for targeted quantification of specific phosphorylation sites

  5. Advanced genetic approaches:

     • Base editing for precise point mutations without double-strand breaks

     • CRISPRi for inducible gene repression during specific cell cycle stages

     • CRISPR activation for controlled overexpression studies

  When implementing these methods, researchers should consider appropriate controls and validation strategies specific to S. pombe cell cycle studies, including synchronization quality checks and careful consideration of tag interference with protein function.

Experimental Troubleshooting Questions

• How can I address non-specific binding issues when using SPAC1851.02 antibody in Western blots?

  To resolve non-specific binding in Western blots with SPAC1851.02 antibody:

  1. Optimization of blocking conditions:

     • Test different blocking agents: 5% non-fat milk, 5% BSA, commercial blocking buffers

     • Extend blocking time to 2 hours at room temperature or overnight at 4°C

     • Add 0.1-0.3% Tween-20 to blocking and antibody solutions

  2. Antibody dilution optimization:

     • Perform titration experiments (1:500 to 1:5000) to identify optimal concentration

     • Prepare antibody in fresh blocking buffer

     • Incubate primary antibody at 4°C overnight rather than at room temperature

  3. Stringent washing procedures:

     • Increase wash duration (5 x 10 minutes)

     • Use TBS-T with higher Tween-20 concentration (0.1-0.3%)

     • Consider adding low concentrations of SDS (0.01-0.05%) to wash buffer for stubborn background

  4. Preabsorption strategies:

     • Preincubate antibody with recombinant SPAC1851.02 protein to confirm specificity

     • For polyclonal antibodies, consider affinity purification against the immunizing antigen

  5. Sample preparation modifications:

     • Include additional protease inhibitors to prevent degradation products

     • Use fresh samples and avoid repeated freeze-thaw cycles

     • Consider native vs. denaturing conditions if epitope recognition is an issue

  6. Validation controls:

     • Include wild-type and SPAC1851.02 deletion strains side by side

     • Use epitope-tagged SPAC1851.02 with commercial tag antibodies as comparison

  Document all optimization steps for reproducibility and future reference.

• What strategies can improve detection sensitivity for low expression levels of SPAC1851.02 in different growth phases?

  For improved detection of low-abundance SPAC1851.02:

  1. Sample enrichment techniques:

     • Subcellular fractionation to concentrate relevant cellular compartments

     • Immunoprecipitation before Western blotting

     • TCA precipitation to concentrate proteins from dilute samples

  2. Enhanced detection systems:

     • Super-signal femto or pico chemiluminescent substrates

     • Fluorescent secondary antibodies with direct scanning

     • Amplification systems like biotin-streptavidin

  3. Growth phase-specific considerations:

     • For logarithmic phase: Harvest cells at precisely OD600 = 0.5-0.8

     • For stationary phase: Extended exposure times and loading higher protein amounts

     • For stress conditions: Compare parallel controls at each time point

  4. Technical modifications:

     • Load higher protein amounts (50-100 μg instead of standard 20-30 μg)

     • Use gradient gels for better separation

     • Transfer proteins to PVDF rather than nitrocellulose membranes

     • Extend primary antibody incubation to 48 hours at 4°C

  5. Signal enhancement through protein stabilization:

     • Add proteasome inhibitors during sample preparation

     • Use phosphatase inhibitors if phosphorylation affects stability

     • Consider crosslinking before lysis to preserve transient complexes

  These approaches should be carefully validated with appropriate controls, including comparison to housekeeping proteins for normalization across different growth conditions.